A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

The purpose of this study is to assess the drug levels, safety, and tolerability of cendakimab in healthy male and female Chinese participants.

Inclusion Criteria:Participants must be Chinese (both biological parents are ethnically Chinese).Body mass index (BMI) of 18.0 through 28.0 kilograms/meter squared (kg/m^2), inclusive. BMI = weight (kg)/[height (m)]^2.Body weight ≥ 50.0 kg.Exclusion Criteria:History of clinically significant infection within 4 weeks of dosing on Day 1.Significant medical history/condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.Condition(s) which may confound the ability to interpret data from the study, as determined by the investigator.Other protocol-defined inclusion/exclusion criteria apply.